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Abstract—Adverse drug reaction (ADR) is widely concerned 
for public health issue. ADRs are one of most common causes 
to withdraw some drugs from market. Prescription event 
monitoring (PEM) is an important approach to detect the 
adverse drug reactions. The main problem to deal with this 
method is how to automatically extract the medical events or 
side effects from high-throughput medical events, which are 
collected from day to day clinical practice. In this study we 
propose a novel concept of feature matrix to detect the ADRs. 
Feature matrix, which is extracted from big medical data from 
The Health Improvement Network (THIN) database, is created 
to characterize the medical events for the patients who take 
drugs. Feature matrix builds the foundation for the irregular and 
big medical data. Then feature selection methods are performed 
on feature matrix to detect the significant features. Finally the 
ADRs can be located based on the significant features. The 
experiments are carried out on three drugs: Atorvastatin, 
Alendronate, and Metoclopramide. Major side effects for each 
drug are detected and better performance is achieved compared 
to other computerized methods. The detected ADRs are based 
on computerized methods, further investigation is needed. 
 
Index Terms— adverse drug reactions, feature matrix, feature 
selection, Atorvastatin, Alendronate, Metoclopramide 
 
1.  Introduction 
Adverse drug reaction (ADR) is widely concerned for 
public health issue. ADRs are one of most common 
causes to withdraw some drugs from market [1]. Now 
two major methods for detecting ADRs are spontaneous 
reporting system (SRS) [2-5], and prescription event 
monitoring (PEM) [6-10]. The World Health 
Organization (WHO) defines a signal in 
pharmacovigilance as “any reported information on a 
possible causal relationship between an adverse event and 
a drug, the relationship being unknown or incompletely 
documented previously” [11]. For spontaneous reporting 
system, many machine learning methods are used to 
detect ADRs, such as Bayesian confidence propagation 
neural network (BCPNN) [12， 13], decision support 
method [14], genetic algorithm [15], knowledge based 
approach [16，17], etc. One limitation is the reporting 
mechanism to submit ADR reports [14], which has 
serious underreporting and is not able to accurately 
quantify the corresponding risk. Another limitation is 
hard to detect ADRs with small number of occurrences of 
each drug-event association in the database. Prescription 
event monitoring has been developed by the Drug Safety 
Research Unit (DSRU) and is the first large-scale 
systematic post-marketing surveillance method to use 
event monitoring in the UK [8]. The health data are 
widely and routinely collected.  It is a key step for PEM 
methods to automatically detect the ADRs from 
thousands of medical events. In paper [18 ， 19], 
MUTARA and HUNT, which are based on a domain-
driven knowledge representation Unexpected Temporal 
Association Rule,  are proposed to signal unexpected and 
infrequent patterns characteristic of ADRs, using 
Queensland Hospital morbidity data, more commonly 
referred to as the Queensland Linked Data Set (QLDS) 
[20]. But their methods achieve low accuracies for 
detecting ADRs.  In the paper [21], four existing ADR 
detecting algorithms were compared by applying them to 
The Health Improvement Network (THIN) database for a 
range of drugs. The results show that the existing 
algorithms are not capable of detecting rare ADRs. Until 
now no successful algorithms are proposed to detect the 
ADRs automatically for PEM methods. 
In this paper we propose a novel approach using 
feature matrix to detect ADRs from The Health 
Improvement Network (THIN) database. First feature 
matrix which represents the medical events for the 
patients before and after taking drugs, is created by 
linking patients’ prescriptions and corresponding medical 
events together. Then significant features are selected 
based on feature selection methods, comparing the 
feature matrix before patients take drugs with one after 
patients take drugs. Finally the significant ADRs can be 
detected from thousands of medical events based on 
corresponding features. Experiments are carried on three 
drugs of Atorvastatin, Alendronate, and Metoclopramide. 
Good performance is achieved.  
The rest of paper is organized as follows. In section 2, 
we introduce feature matrix and how to extract it from 
THIN database. Two feature selection methods are 
described in section 3. The experiments are conducted in 
section 4 based on three drugs, followed by discussion in 
section 5. Conclusions are made in section 6.  
2. Feature matrix 
A novel concept of feature matrix is proposed to 
represent data and detect ADRs, using feature selection 
methods.  Normally patients take drugs for different 
periods of time, and have different numbers of repeated 
prescriptions. The longer the period of time, the more the 
medical events related to the drug. How to represent the 
high-throughput data related to prescriptions and medical 
events, is a key step to detect the ADRs. Feature matrix 
builds the basis of saving data and comparing data. Two 
kinds of feature matrix are built in this study, based on 
medical events using Readcodes at level 1-5 and 
Readcodes at level 1-3, respectively.  The medical events 
using Readcodes at level 1-3 give the general term, 
whereas those using Readcodes at level 1-5 give more 
specific descriptions.  
 
2.1 The THIN database 
The Health Improvement Network (THIN) is a 
collaboration product between two companies of EPIC 
and InPS. EPIC is a research organisation, which 
provides the electronic database of patient care records 
from UK and other countries. InPS continue to develop 
and supply the widely-used Vision general practice 
computer system. The anonymised patient data are 
collected from the practice's Vision clinical system on a 
regular basis without interruption to the running of the 
GP’s system and sent to EPIC who supplies the THIN 
data to researchers for studies. Research studies for 
publication using THIN Data are approved by a 
nationally accredited ethics committee which has also 
approved the data collection scheme. 
There are ‘Therapy’ and ‘Medical’ databases in THIN 
data. The “Therapy” database contains the details of 
prescriptions issued to patients. Information of patients 
and the prescription date for the drug can be obtained. 
The “Medical” database contains a record of symptoms, 
diagnoses, and interventions recorded by the GP and/or 
primary care team. Each event for patients forms a 
record. By linking patient identifier, their prescriptions, 
and their corresponding medical events or symptoms 
together, feature matrix to characterize the symptoms 
during the period before or after patients take drugs is 
built. 
 
2.2 Readcodes and feature matrix 
Medical events or symptoms are represented by 
medical codes, named Readcodes. There are 103387 
types of medical events in “Readcodes” database. The 
Read Codes used in general practice (GP), were invented 
and developed by Dr James Read in 1982. The NHS 
(National Health Service) has expanded the codes to 
cover all areas of clinical practice. The code is 
hierarchical from left to right or from level 1 to level 5. It 
means that it gives more detailed information from level 
1 to level 5.  Table 1 shows the medical symptoms based 
on Readcodes at level 3 and at level 5.  ‘Other soft tissue 
disorders’ is general description using Readcodes at level 
3.  ‘Foot pain’, ‘Heel pain’, etc., give more details using 
Readcodes at level 5. ‘Other extrapyramidal disease and 
abnormal movement disorders’ is general term; ‘Restless 
legs syndrome’, ‘Essential and other specified forms of 
tremor’, etc., are detailed descriptions using Readcodes at 
level 5.  
In this research, two kinds of feature matrix are built to 
characterize the symptoms of patients who take drugs. 
One is based on Readcodes at level 1-5, which cover all 
the symptoms and detailed information which occur when 
patients take drugs. Another one is based on Readcodes at 
level 1-3, which is created by combining the detailed 
symptoms using Readcodes at level 4-5 into the general 
term using Readcodes at level 3. For the drug of 
Alendronate, ‘Temporomandibular joint disorders’ of 
‘J046.00’ at level 4 is a typical ADR, but ‘Dentofacial 
anomalies’ of ‘J04..00’ at level 3 is more general term for 
this particular ADR. If patients have the symptom of 
‘Temporomandibular joint disorders’ (‘J046.00’) in 
feature matrix based Readcodes at 1-5, after we merge 
the detailed descriptions into the general term, a new 
feature matrix based on Readcodes at level 1-3 is rebuilt 
instead of using ‘Dentofacial anomalies’ (‘J04..00’) . 
 
2.3 The extraction of feature matrix 
To detect the ADRs of drugs, first feature matrix is 
extracted from THIN database, which describes the 
medical events that patients occur before or after taking 
drugs. Then feature selection methods of Student’s t-test 
and Wilcoxon rank sum test are performed to select the 
significant features from feature matrix containing 
thousands of medical events.  Figure 1 shows the process 
to detect the ADRs using feature matrix. Feature matrix 
A  (Figure 2) describes the medical events for each 
patient during 60 days before they take drugs. Feature 
matrix B  is one after patients take drugs. For repeated 
prescriptions, all the medical events related to each 
prescription of patients are input to build the feature 
matrix. When the interval between two adjacent 
prescriptions is less than 60 days, we put all the medical 
events between two adjacent into feature matrix after 
patients take drugs. When the interval between two 
prescriptions is more than 60 days, the medical events 
within 60 days after the first prescription are used build 
the feature matrix after patients take drugs, and the 
medical events beyond 60 days are put into the feature 
matrix before patients take drugs. Figure 3 shows how to 
extract feature matrix. Figure 4 shows the flowchart of 
building feature matrix.  
In order to reduce the computation time and save the 
computation space, we set 100 patients as a group. Matrix 
X  and Y  are feature matrix after patients are divided 
into groups.   
Feature matrix A  and B  are defined as follows: 
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where variable i and j represent patients and medical 
events. Variable m and n represent the number of 
patients and medical events respectively. 1=ija  is for 
the state where ith patient has jth medical event; 
otherwise 0=ija . Feature matrix A and B describe the 
medical events during 60 days before or after patients 
take drugs.  
Feature matrix X  and Y  are defined as follows: 
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where variable g represents the number of groups. 
Variable kjx represents the patient number of kth group 
having jth medical event. In this study, each group 
contains 100 patients, and d is set to 100. 
3. Feature selection 
After two feature matrixes are obtained, which 
represent the medical events before and after patients take 
drugs, feature selection methods are performed to detect 
the significant features that reflect the significant 
changes. Feature selection methods normally have two 
classes. One class is “wrapper” methods, which select 
feature subsets based on classification performance, such 
as genetic algorithm [22， 23]. Another one is filter 
methods, which select features based on between-class 
discriminant criterion, give the ranked features, and are 
not involved in classification performance in the process 
of feature selection, such as Student’s t-test and Wilcoxon 
rank-sum test.  
Obviously, in this study, it is not the classification 
problem. The main idea is to find which medical event 
changes significantly and give their ranks. We employ 
feature selection methods of Student’s t-test and 
Wilcoxon rank-sum test, which are based on the data 
assumption having normal distribution and no 
assumptions for data distributions, respectively. Based on 
doctors’ suggestion, the ratio of the patient number after 
taking the drug to one before taking the drug for having 
one particular symptom is also used to represent the 
changes of symptoms. 
 
3.1 Student’s t-test 
Student’s t-test [24] feature selection method is used to 
detect the significant ADRs from thousands of medical 
events. Student’s t-test is a kind of statistical hypothesis 
test based on a normal distribution, and is used to 
measure the difference between two kinds of samples. 
Student’s t-test calculates a score it to measure the 
difference between feature matrix X  and Y , which 
represents the importance of jthmedical event or ADR 
among all groups of patients. 
Student’s  t-test is defined as follows: 
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where jx and jy represent the means of two groups of 
samples, xjS and yjS represent the standard deviations of 
two groups of samples. xM and yM represent the 
number of two groups of samples.  
 
3.2 Wilcoxon rank-sum test 
Student’s t-test assumes that the data follow a normal 
distribution. If no assumption can be made about the 
shape of the population distribution, non-parametric 
statistical methods can be used. The Wilcoxon rank-sum 
test is a non-parametric analogue to Student’s t-test for 
two independent samples. It is used for the determination 
of equality of the means of two non-normal samples. The 
test is based on the rank of the individual data within 
feature matrix. As it operates on rank-transformed data, it 
also is a robust choice for detecting the significant 
medical symptoms. In this test, the ranking of data is 
performed first by giving the highest rank (equal to the 
number of features) to the feature with the highest value, 
and the lowest rank to the feature with lowest value. The 
ranks for remaining features are assigned using the rank-
sum test as explained in details in [25]. 
 
3.3 Other parameters 
The variable of ratio 
1R is defined to evaluate 
significant changes of the medical events, using ratio of 
the patient number after taking the drug to one before 
taking the drug.  The variable 
2R  represents the ratio of 
patient number after taking the drug to the number of 
whole population having one particular medical 
symptom. 
The ratio variables 
1R and 2R  are defined as follows: 
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where 
BN and AN  represent the numbers of patients 
before or after they take drugs for having one particular 
medical event respectively. The variable N  represents 
the number of whole population who take drugs. 
We compare our proposed method with published 
results in [19]. Same evaluation standard is used in our 
research. Accuracy is defined as follows: 
alladr NNACC =  
where ACC represents the accuracy to predict the 
ADRs. adrN  represents the number of true positive 
(ADRs), and allN  represents the number of whole 
number for prediction. In this research we only evaluate 
top 20  results of prediction, and allN is set to 20. 
 
4. Experiments and results 
Three drugs of Atorvastatin, Alendronate, and 
Metoclopramide are used to test our proposed method, 
using 20 GPs data in THIN database. The drug of 
Atorvastatin is one of ‘statin’ class and has the particular 
‘muscle pain’ side effects. For the drug of Alendronate, 
the ‘Temporomandibular joint disorders’ is a typical 
ADR. The drug of Metoclopramide has the typical ADR 
of ‘extrapyramidal effects’ or ‘abnormal movement 
disorders’. So in this study, three drugs that have different 
typical ADRs, are used to test our proposed method. Jin 
et al. also use the drugs of Atorvastatin and Alendronate 
to test their proposed methods of MUTARA and HUNT 
[18,19].  
Student’s t-test and Wilcoxon rank-sum test are 
performed to select the significant features from feature 
matrix, which represent the medical events having the 
significant changes after patients take the drugs. In 
experiments, we use two kinds of feature matrix. One 
feature matrix is based on all medical events using 
Readcodes at level 1-5 in order to observe the detailed 
symptoms. Another one is based on the medical events 
using Readcodes at leve1 1-3, by combining the detailed 
information of Readcodes at level 4 and 5 into general 
terms using Readcodes at level 3.  
 
Some common abbreviations used in the ‘Readcodes’ 
dictionary are shown as below: 
C/O      Complains of  
H/O History of  
NOS Not otherwise specified  
F/H  Family history  
O/E on examination  
[M] Morphology of neoplasms  
[D] Working diagnosis  
 
4.1 Atorvastatin 
Atorvastatin [26], under the trade name Lipitor, is one 
of the drugs known as statins. It is used for lowering 
blood cholesterol. There are seven currently prescribed 
forms of statin drugs. They are Rosuvastatin, 
Atorvastatin, Simvastatin, Pravastatin, Fluvastatin, 
Lovastatin, Pitavastatin. Muscle pain and musculoskeletal 
events are two of the main side effects of statin drugs 
[27]. 
Drugs.com provides access to healthcare information, 
sourced solely from the most trusted, well-respected and 
independant agents such as the Food and Drug 
Administration (FDA), American Society of Health-
System Pharmacists, Wolters Kluwer Health, Thomson 
Micromedex, Cerner Multum and Stedman's. The side 
effects for Atorvastatin [28] by Drugs.com are severe 
allergic reactions (rash; hives; itching; difficulty 
breathing or swallowing; tightness in the chest; swelling 
of the mouth, face, lips, throat, or tongue); burning, 
numbness, or tingling; change in the amount of urine 
produced; confusion; memory problems; mental or mood 
problems (eg, depression); muscle pain, tenderness, or 
weakness (with or without fever or fatigue); painful, 
difficult, or frequent urination; persistent pain, soreness, 
redness, or swelling of a tendon or joint; red, swollen, 
blistered, or peeling skin; severe stomach or back pain 
(with or without nausea or vomiting); symptoms of liver 
problems (eg, dark urine; pale stools; severe or persistent 
nausea, loss of appetite, or stomach pain; unusual 
tiredness; yellowing of the skin or eyes).  
We only use the data for patients, who registered on 
GP for more than one year, in order to obtain the reliable 
data. 6803 patients take Atorvastatin from 20GP data in 
THIN database. Based on Readcodes at level 1-5, totally 
10528 medical events are obtained before or after 6803 
patients take the drug. So 6803x10528 feature matrix is 
obtained. Based on Readcodes at level 1-3, we combine 
the medical events which have the same first three codes 
into one medical event, just using first three codes. 10528 
medical events based on Readcodes at level 1-5 are 
combined into 2350 medical events based on Readcodes 
at level 1-3, and a 6803x2350 feature matrix is created. 
After grouping patients, 68x10528 and 68x2350 feature 
matrix are formed to select the significant features, which 
reflect the significant change of medical events after 
patients take drugs. 
Table 2 and Table 3 show the top 20 ADRs for 
Atorvastatin based on Student’s t-test and Wilcoxon rank-
sum test, using medical events based on Readcodes at 
level 1-5 and level 1-3. From Table 2 and 3, it is clear 
that the detected ADRs are consistent with the published 
side effects for Atorvastatin. The difference for the 
detected ADRs between Student’s t-test and Wilcoxon 
rank-sum test is that the rank of the ADRs is different. 
For example the medical event of ‘Other soft tissue 
disorder’ is rank 3 based on Student’s t-test, and rank 12 
based on Wilcoxon rank-sum test. ‘Other soft tissue 
disorder’ is major side effect for statin. From this view, 
the detected ADRs based on Student’s t-test are better 
than those based on Wilcoxon rank-sum test.  
Our detected ADRs are classified into several 
categories, such as muscle pain, muscle weakness and 
neuropathy, gastrointestinal events, musculoskeletal 
events [27], skin and subcutaneous tissue events [28], 
bronchitis and bronchiolitis [29] diabetes mellitus events 
[30， 31]. Good performance of 100% accuracy is 
achieved for the top 20 ADRs based on Student’s t-test 
and Wilcoxon rank-sum test.  
MUTARA and HUNT [18，19] based on Unexpected 
Temporal Association Rule are proposed to signal 
unexpected and infrequent patterns characteristic of 
ADRs, using The Queensland Linked Data Set (QLDS). 
They indicated that “HUNT can reliably shortlist 
statistically significantly more ADRs than MUTARA”. 
For the drug of Atorvastatin, HUNT detects 4 ADRs of 
‘urinary tract infection’, ‘stomach ulcer’, ‘diarrhoea’, and 
‘bronchitis’ from top 20 results based on 13712 patient 
records, and only obtains 30% average accuracy [19]. 
The major side effects of Atorvastatin, such as muscle 
pain and musculoskeletal events, are not detected. Table 
4 shows the performance of HUNT and MUTARA. Our 
proposed method detects ‘muscle and musculoskeletal’ 
events not only based on Readcodes at level 1-5, but also 
based on Readcodes at level 1-3. ‘Peripheral 
enthesopathies and allied syndromes’ and ‘Other soft 
tissue disorders’ are detected at rank 2 and 3 based on 
Readcodes at level 1-3, using feature selection method of 
Student’s t-test. 
  
4.2 Alendronate 
Alendronate sodium, sold as Fosamax by Merck, is a 
bisphosphonate drug used for osteoporosis and several 
other bone disease [32]. The side effects for Alendronate 
[ 33] are severe allergic reactions (rash; hives; itching; 
difficulty breathing; tightness in the chest; swelling of the 
mouth, face, lips, throat, or tongue); black, tarry, or 
bloody stools; chest pain; coughing or vomiting blood; 
difficult or painful swallowing; mouth sores; new, 
worsening, or persistent heartburn; red, swollen, 
blistered, or peeling skin; severe bone, muscle, or joint 
pain (especially in the hip, groin, or thigh); severe or 
persistent sore throat or stomach pain; swelling of the 
hands, legs, or joints; swelling or pain in the jaw; 
symptoms of low blood calcium (eg, spasms, twitches, or 
cramps in your muscles; numbness or tingling in your 
fingers, toes, or around your mouth).   
In [32], side effects include ulceration of the 
esophagus, gastric and duodenal ulceration, skin rash, 
rarely manifesting as Stevens–Johnson syndrome and 
toxic epidermal necrolysis, eye problems (uveitis, 
scleritis),  generalized muscle, joint, and bone pain, 
osteonecrosis of the jaw or deterioration of the 
Temporomandibular Joint (TMJ), auditory hallucinations, 
visual disturbances. Studies suggest that users of 
alendronate have an increase in the numbers of 
osteoclasts and develop giant, more multinucleated 
osteoclasts. Fosamax has been linked to a rare type of leg 
fracture that cuts straight across the upper thigh bone 
after little or no trauma. 
3346 patients from 20GP data in THIN database are 
taking Alendronate, and 7260 medical events are 
obtained based on Readcodes at level 1-5. After grouping 
them, 33x7260 feature matrix is obtained. For Readcodes 
at level 1-3, 33x1964 feature matrix is obtained. Table 5 
and 6 show the top 20 ADRs based on Student’s t-test 
and Wilcoxon rank-sum test. Our results show that most 
detected ADRs are consistent with the published results 
[32]. ‘Chronic kidney disease stage 3’, ‘Type 2 diabetes 
mellitus’, and ‘Essential hypertension’ are not listed in 
[32]. 85% accuracy is achieved. But in [34], ’acute renal 
failure’ is reported after the patient takes Alendronate. 
‘Based on the study created by eHealthMe from U.S. 
Food and Drug Administration (FDA) and user 
community [35], 0.60% patients have ‘Type 2 diabetes 
mellitus’. In [36], 0.62% patients have ‘Essential 
hypertension’.  For HUNT, only ‘headache’, ‘swelling’, 
wheeze’, ‘breathing difficult’, ‘heart burn’, and 
‘constipation’ are detected in top 20 ADRs based on 7569 
patients.  Totally 30% average accuracy is obtained. The 
major side effect of ‘muscle or joint pain’ is not detected.  
‘Peripheral enthesopathies and allied syndromes’ and 
‘Other soft tissue disorders’ with rank 14 and 15 are 
detected to describe the ADRs related to ‘muscle or joint 
pain’, which are listed in Table 5 using Readcodes at 
level 1-3 based on Student’s t-test. But they are not list in 
Table 6 based on Wilcoxon rank-sum test in top 20 
ADRs. From this view, Student’s t-test method is better 
than Wilcoxon rank-sum test. 
After we obtain the results using Student’s t-test with 
p<0.05, which reflect the significant changes after 
patients take drug, then we also sort the order of results 
according to descending order of  R1 value. Table 7 
shows top 20 ADRs based on the descending order of R1 
value. From Table 7, we notice that the typical side effect 
‘Temporomandibular joint disorders’ for Alendronate’ is 
detected at rank 11 using Readcodes at level 1-5.  
 
4.3  Metoclopramide 
Metoclopramide is used to treat nausea and vomiting 
associated with conditions such as uremia, radiation 
sickness, malignancy, labor, infection, migraine 
headaches, and emetogenic drugs [37].  The side effects 
[38] for Metoclopramide are severe allergic reactions 
(rash; hives; itching; difficulty breathing; tightness in the 
chest; swelling of the mouth, face, lips, or tongue; 
unusual hoarseness); abnormal thinking; confusion; dark 
urine; decreased balance or coordination; decreased 
sexual ability; fast, slow, or irregular heartbeat; fever; 
hallucinations; loss of bladder control; mental or mood 
changes (eg, depression, anxiety, agitation, jitteriness); 
seizures; severe or persistent dizziness, headache, or 
trouble sleeping; severe or persistent restlessness, 
including inability to sit still; shortness of breath; stiff or 
rigid muscles; sudden increased sweating; sudden, 
unusual weight gain; suicidal thoughts or actions; 
swelling of the arms, legs, or feet; uncontrolled muscle 
spasms or movements (eg, of the arms, legs, tongue, jaw, 
cheeks; twitching; tremors); vision changes; yellowing of 
the skin or eyes. In [37] common adverse drug reactions 
associated with metoclopramide therapy include 
restlessness, drowsiness, dizziness, fatigue, and focal 
dystonia. Infrequent ADRs include hypertension, 
hypotension, hyperprolactinaemia leading to 
galactorrhea, constipation, depression, headache, and 
extrapyramidal effects such as oculogyric crisis. 
8320 patients from 20 GPs take Metoclopramide. 8094 
medical events are obtained using Readcodes at level 1-5, 
and 8320x8094 feature matrix is created. After 8094 
medical events are combined into 2117 medical 
symptoms based on Readcodes at level 1-3, 8320x2117 
feature matrix is created. After patients are grouped, 
83x8094 feature matrix is formed using Readcodes at 
level 1-5, and 83x2117 feature matrix is obtained using 
Readcodes at level 1-3. Table 8 and 9 show the top 20 
detected results in ascending order of p value of Student’s 
t-test and Wilcoxon rank-sum test, using Readcodes at 
level 1-5 and at level 1-3, respectively. 
From Table 8 and 9, it is shown that the typical side 
effect ‘Other extrapyramidal disease and abnormal 
movement disorders’ for Metoclopramide is detected at 
rank 3 and rank 4 based on Student’s t-test and Wilcoxon 
rank-sum test. The top 20 medical events cover most 
important side effects for the drug of Metoclopramide. 
The side effect ‘Cholangitis’ is detected at rank 14 in 
Table 8 based on Student’s t-test using Readcodes at level 
1-5. In [38], a 22-year-old female, treated with 
metoclopramide for 7 to 8 months for abdominal pain, 
developed hepatic hemangiomatosis with arteriovenous 
shunting and cholestasis.  
The ADRs having top ranks (rank 1,2,3,5) are ‘patient 
died’ based on Student’s t-test using Readcodes at level 
1-5, and they are not listed in [37，38]. So our result 
achieves 80% accuracy. But based on the study created 
by eHealthMe from FDA and user community, 1.93% 
patients have ‘Death’ [39]. We notice that three patients 
are ‘died’ before they took the drug. Actually, the real 
state for these patients is ‘expected died’.  
5. Discussion  
5.1 Feature matrix 
In this research, we propose the novel concept of feature 
matrix. For the medical data which are collected from day 
to day clinical practice, they are irregular and 
magnanimity data. Each patient has different medical 
information. Even for the same drug, different patients 
have taken drugs at different time points and different 
periods, and have different medical symptoms. How to 
extract the useful information after patients take drugs is 
first and key step to detect the adverse drug reactions. A 
novel concept of feature matrix is proposed to store and 
characterize the common information that only deal with 
symptoms before and after taking drugs for patients. For 
each drug, its corresponding feature matrix is built to 
cover all the symptoms or medical events occurred before 
or after taking the drug for all patients. Feature matrix 
transfers the unrelated information of different patients to 
common saving format, and builds the foundation to 
detect the adverse drug reactions. For example, some 
patients take the “statin” drugs for years, and the 
corresponding prescriptions and medical events are 
“mass” information. But we only interest the information 
before and after taking drugs, feature matrix are built to 
characterize the representative features extracted from 
THIN database, which is collected day to day clinical 
practice. All the prescriptions during the period of taking 
drugs are checked. The medical events during 60 days 
before or after each prescription are used to build the 
feature matrix for this drug. This is reason that chronic 
side effects can be detected. For example, for the drug of 
Alendronate, one chronic side effect is 
“Temporomandibular joint disorders”, which is detected 
by our proposed method.   
Two kinds of feature matrix are created to represents 
the medical events or symptoms for patients before and 
after taking drugs. One type of feature matrix is to use 
original data based on Readcodes at level 1-5. Another 
one is based on Readcodes at level 1-3, combining the 
medical symptoms using Readcodes at level 4-5 into one 
using Readcodes at level 3. For example, ‘Type 2 
diabetes mellitus’ has Readcodes of ‘C10F.00’ at level 4, 
and Readcodes of ‘C10..00’ at level 3 represents the 
general term of ‘Diabetes mellitus’. 
 
5.2 Feature selection and the performance  
In this research, we compare our proposed method 
with published results in [19]. In paper [19], two drugs of 
Atovastatin and Alendronate are used to test their 
proposed methods, and average 30% accuracy is obtained 
in [19]. Their proposed methods do not detect two major 
side effects of muscle pain and musculoskeletal events.  
Same evaluation standard is used in our research. Our 
proposed methods based on extracted feature matrix and 
feature selection, achieve good results. For drug 
Atovastatin and Alendronate, major ADRs are detected, 
and 100% and 85% accuracy are obtained. For 
Atorvastatin, the major side effect of ‘muscle pain’ is 
detected at rank 3, which is ‘Other soft tissue disorders’ 
using Readcodes at level 1-3. For the drug of 
Alendronate, the typical side effect of 
‘Temporomandibular joint disorders’ is detected at rank 1 
based on the descending order of the ratio of the patient 
number after taking the drug to one before taking the 
drug, which is ‘Dentofacial anomalies’ using Readcodes 
at level 1-3. For the drug of Metoclopramide, the typical 
ADR of ‘abnormal movement disorders’ is detected at 
rank 3, which is ‘Other extrapyramidal disease and 
abnormal movement disorders’ using Readcodes at level 
1-3.  
Feature selection is widely used to reduce data 
dimensionality and detect the significant features [40,41]. 
In this research feature selection methods of Student’s t-
test and Wilcoxon rank-sum test are employed to detect 
the significant changes of feature matrix. Student’s t-test 
assumes that the data follow a normal distribution. 
Wilcoxon rank-sum test has no assumption about the 
shape of data distribution. Experimental results show that 
Student’s t-test achieves better performance than 
Wilcoxon rank-sum test.  The variable of ratio of the 
patient number after taking the drug to one before taking 
the drug is complementary part for Student’s t-test 
method. The ratio variable is useful to detect the some 
typical ADRs.  
Because of the creation of feature matrix, its unique 
saving format makes it possible to combine medical 
symptoms using Readcodes at level 4-5 into one using 
Readcodes at level 3. Feature matrix using Readcodes at 
level 1-5 gives the detail information, and feature matrix 
using Readcode at level 1-3 can extracts the general 
symptoms, which may be not noticed using feature matrix 
using Readcodes at level 1-5, for example the ADR of 
“extrapyramidal disease and abnormal movement 
disorder” for drug Metoclopramide.  
 
5.3 Rare ADRs, chronic ADRs, drug interaction, and 
advantages  
Our proposed method has successfully shortlisted the 
rare ADRs of “Temporomandibular joint disorders” for 
drug Alendronate, “extrapyramidal disease and abnormal 
movement disorder” for drug Metoclopramide, and the 
research work in [21] indicated that the existing 
algorithms are not capable of detecting rare ADRs.  
The ADRs are rare, and it means the frequency to 
appear is low. If the methods detect the ADRs only based 
on the frequency of ADR appearing, there is never 
sufficient data to support the hypothesis of a causal 
relationship between the drug and the reaction.  
The rare ADRs of “Temporomandibular joint 
disorders” for drug Alendronate and “extrapyramidal 
disease and abnormal movement disorder” for drug 
Metoclopramide are from 3346 and 8320 patients. 
Enough data is used to support the detection of ADRs. 
Our proposed method is not only based on the frequency 
of ADR appearing, and but also is based on the 
significant change of medical symptoms. The rare ADRs 
may not appear frequently, but make the significant 
change. So our proposed method can detect rare ADRs. 
When feature matrix is built, all the prescriptions of 
each patient for this drug are checked to extract the 
information, no matter how long the patient takes this 
drug. Because of the characteristics of feature matrix, 
chronic side effects can be detected. Exiting algorithms 
[18，19] only check the prescriptions during some period 
of time, and lose part of the information of side effects.  
Because of the characteristics of feature matrix, it is 
easy to trace the information of patients having the 
particular ADRs, and extract the information of other 
drugs taken by these patients. This gives the foundation 
to do further research of drug interactions. 
Two advantages are achieved in this research 
compared with exiting algorithms. One is to propose 
feature matrix, which transfers the irregular information 
of each patient during whole period of taking drugs into 
standard saving format. This makes it possible to detect 
chronic ADRs. Another one is based on the changing 
degree of symptoms to detect the ADRs. This makes it 
possible to detect rare ADRs. 
6. Conclusions 
In this study we propose a novel method to 
successfully detect the ADRs by introducing feature 
matrix and feature selection to detect the significant 
changes after patients take drugs. A feature matrix, which 
characterizes the medical events before patients take 
drugs or after patients take drugs, is created from THIN 
database. Feature matrix transfers the irregular and high-
throughput medical data collected from daily basis into 
feature matrix of standard saving format, and is a 
foundation to perform feature selection methods. Feature 
selection methods based on Student’s t-test and Wilcoxon 
rank-sum test are used to detect the significant features 
from high dimensional feature matrix. The significant 
ADRs, which are corresponding to significant features, 
are detected. Experiments are performed on three drugs: 
Atorvastatin, Alendronate, and Metoclopramide. 
Compared to other computerized method, our proposed 
method achieves better performance. The detected ADRs 
are based on computerized methods, further investigation 
is needed. 
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Fig. 1. The process to detect ADRs. Matrix A  and B  are feature matrix before or after patients take drugs. The time period of 
observation is set to 60 days. Matrix X  and Y  are feature matrix after patients are divided into groups. We set 100 patients as one 
group. 
 
 
Fig. 2. Feature matrix. The row of feature matrix represents the patients, and the column of feature matrix represents the medical 
events. The element of events is 1 or 0, which represents that patients have or do not have the corresponding medical symptom or 
event.  
 
Fig.3. The building process of feature matrix. Feature matrix A reflects the medical events for each patient during 60 days before 
they take drugs. Feature matrix B is one after patients take drugs. Time axis covers time points of prescriptions and medical events 
during the whole time for the patients taking drug. Variable p1,p2,p3 and p4 (☆) represent the time points of prescriptions for the 
patient taking the drug. Variable e1,e2,..., and e8 (○) represent the time points of medical symptoms for the patient. The interval T1 
between p1 and p2 is 60<T1<120 days. The interval T2 between p2 and p3 is T2>120 days. The interval T3 between p3 and p4 is 
<=60 days.  
  
 
 
Fig. 4. The flowchart of building feature matrix. Feature matrix A reflects the medical events for each patient during 60 days before 
they take drugs. Feature matrix B is one after patients take drugs. Two datasets of medical events E and prescriptions P include all 
the medical events and prescriptions of patients taking the drug. The datasets of E and P are extracted from THIN database, and all 
the data are sorted in ascending order along the time. Variable pl and ek represent the time points for the prescription (l) and the 
medical event (k) respectively. Variable k (k=1,...,N) and l (l=1,...,M) represent the number or position of the medical event in dataset 
E and the prescriptions in dataset P respectively. Variable S represents the dataset including all the types of medical events in A and 
B. Variable r represents the type number of medical events in S. Variable i and j represent ith patient and jth medical event 
respectively. Variable mk represents the kth medical event in dataset E. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1. Medical events based on Readcodes at level 1-3 and level 1-5.  
 Level Readcodes Medical events 
 
Other soft  
tissue disorders  
 Level 3   N24..00  Other soft tissue disorders  
 
 
Level 5 
  N245.16  Leg pain  
  N245111  Toe pain  
  N241012   Muscle pain 
  N242000  Neuralgia unspecified  
  N241000  Myalgia unspecified 
 
Abnormal  
movement 
 Level 3 F13..00 Other extrapyramidal disease and abnormal movement disorders 
 
 
Level 5 
F13z200  Restless legs syndrome 
F131000 Benign essential tremor 
F131z00 Essential and other specified forms of tremor 
F132z12  Myoclonic seizure 
F132300  Myoclonic jerks 
 
 
Table 2. The top 20 ADRs for Atorvastatin based on Student’s t-test. 
 Rank Readcodes Medical events NB NA R1(%) R2 (%) 
 
 
 
 
Level 1-5 
1 1A55.00 Dysuria 26 181 6.96 2.66 
2 1Z12.00 Chronic kidney disease stage 3 63 477 7.57 7.01 
3 N131.00 Cervicalgia - pain in neck 73 337 4.62 4.95 
4 N143.00 Sciatica 48 205 4.27 3.01 
5 F4C0.00 Acute conjunctivitis 60 274 4.57 4.03 
6 N245.17 Shoulder pain 99 376 3.80 5.53 
7 M03z000 Cellulitis NOS 57 264 4.63 3.88 
8 1C14.00 "Blocked ear" 13 120 9.23 1.76 
9 A53..11 Shingles 17 121 7.12 1.78 
10 H01..00 Acute sinusitis 44 194 4.41 2.85 
11 1M10.00 Knee pain 103 369 3.58 5.42 
12 19EA.00 Change in bowel habit 17 102 6.00 1.50 
13 H06z000 Chest infection NOS 136 563 4.14 8.28 
14 C10F.00 Type 2 diabetes mellitus 154 436 2.83 6.41 
15 1D14.00 C/O: a rash 70 357 5.10 5.25 
16 M0...00 Skin and subcutaneous tissue infections 18 115 6.39 1.69 
17 N247100 Leg cramps 36 132 3.67 1.94 
18 M111.00 Atopic dermatitis/eczema 36 190 5.28 2.79 
19 19F..00 Diarrhoea symptoms 52 244 4.69 3.59 
20 H33..00 Asthma 23 106 4.61 1.56 
 
 
 
 
 
 
Level 1-3 
1 171..00 Cough 309 1105 3.58 16.24 
2 N21..00 Peripheral enthesopathies and allied syndromes 136 568 4.18 8.35 
3 N24..00 Other soft tissue disorders 462 1371 2.97 20.15 
4 1Z1..00 Chronic renal impairment 79 570 7.22 8.38 
5 1B1..00 General nervous symptoms 204 667 3.27 9.80 
6 19F..00 Diarrhoea symptoms 97 444 4.58 6.53 
7 M22..00 Other dermatoses 94 353 3.76 5.19 
8 1C1..00 Hearing symptoms 43 269 6.26 3.95 
9 183..00 Oedema 97 433 4.46 6.36 
10 N13..00 Other cervical disorders 81 362 4.47 5.32 
11 1B8..00 Eye symptoms 73 322 4.41 4.73 
12 F4C..00 Disorders of conjunctiva 85 381 4.48 5.60 
13 H06..00 Acute bronchitis and bronchiolitis 357 1161 3.25 17.07 
14 173..00 Breathlessness 198 675 3.41 9.92 
15 1A5..00 Genitourinary pain 56 276 4.93 4.06 
16 M03..00 Other cellulitis and abscess 73 357 4.89 5.25 
17 N09..00 Other and unspecified joint disorders 196 721 3.68 10.60 
18 1D1..00 C/O: a general symptom 159 695 4.37 10.22 
19 A53..00 Herpes zoster 20 158 7.90 2.32 
20 J57..00 Other disorders of intestine 48 222 4.63 3.26 
Variable NB and NA represent the numbers of patients before or after they take drugs for having medical events.  Variable  R1 represents the ratio 
of the numbers of patients after taking drugs to the numbers of patients before taking drugs for having one particular ADR. Variable  R2  
represents the ratio of the numbers of patients after taking drugs to the number of the whole population for having one particular ADR. 
 
Table 3. The top 20 ADRs for Atorvastatin based on Wilcoxon rank-sum test. 
 Rank Readcodes Medical events NB NA R1(%) R2 (%) 
 
 
 
 
 
Level 1-5 
 1  1Z12.00           Chronic kidney disease stage 3      63     477    7.57      7.01 
  2  1A55.00                                  Dysuria      26     181    6.96      2.66 
  3  N131.00               Cervicalgia - pain in neck      73     337    4.62      4.95 
  4  M03z000                           Cellulitis NOS      57     264    4.63      3.88 
  5  C10F.00                 Type 2 diabetes mellitus     154     436    2.83      6.41 
  6  A53..11                                 Shingles      17     121    7.12      1.78 
  7  N143.00                                 Sciatica      48     205    4.27      3.01 
  8  F4C0.00                     Acute conjunctivitis      60     274    4.57      4.03 
  9  1C14.00                            "Blocked ear"      13     120    9.23      1.76 
 10  N245.17                            Shoulder pain      99     376    3.80      5.53 
 11  H01..00                          Acute sinusitis      44     194    4.41      2.85 
 12  K190.00 Urinary tract infection, site not specified      56     271    4.84      3.98 
 13  19EA.00                    Change in bowel habit      17     102    6.00      1.50 
 14  M0...00  Skin and subcutaneous tissue infections      18     115    6.39      1.69 
 15  M223.00                    Seborrhoeic keratosis      15      99    6.60      1.46 
 16  H33..00                                   Asthma      23     106    4.61      1.56 
 17  N245.13                                Foot pain      36     165    4.58      2.43 
 18  C34..00                                     Gout      66     194    2.94      2.85 
 19  G573000                      Atrial fibrillation      51     144    2.82      2.12 
 20  M21z100                                 Skin tag      14      86    6.14      1.26 
 
 
 
 
Level 1-3 
 1  1C1..00                         Hearing symptoms      43     269    6.26      3.95 
  2  1Z1..00                 Chronic renal impairment      79     570    7.22      8.38 
  3  H06..00       Acute bronchitis and bronchiolitis     357    1161    3.25     17.07 
  4  M03..00             Other cellulitis and abscess      73     357    4.89      5.25 
  5  N21..00 Peripheral enthesopathies and allied syndromes     136     568    4.18      8.35 
  6  J57..00             Other disorders of intestine      48     222    4.63      3.26 
  7  171..00                                    Cough     309    1105    3.58     16.24 
  8  A53..00                            Herpes zoster      20     158    7.90      2.32 
  9  173..00                           Breathlessness     198     675    3.41      9.92 
 10  M22..00                         Other dermatoses      94     353    3.76      5.19 
 11  K19..00 Other urethral and urinary tract disorders     101     496    4.91      7.29 
 12  N24..00              Other soft tissue disorders     462    1371    2.97     20.15 
 13  19F..00                       Diarrhoea symptoms      97     444    4.58      6.53 
 14  183..00                                   Oedema      97     433    4.46      6.36 
 15  F42..00                  Other retinal disorders      65     320    4.92      4.70 
 16  1B1..00                 General nervous symptoms     204     667    3.27      9.80 
 17  F4C..00                 Disorders of conjunctiva      85     381    4.48      5.60 
 18  1A5..00                       Genitourinary pain      56     276    4.93      4.06 
 19  H01..00                          Acute sinusitis      53     236    4.45      3.47 
 20  1B8..00                             Eye symptoms      73     322    4.41      4.73 
 
Table 4. The accuracy of HUNT and MUTARA [19]. 
               Experimental settings  Signalling accuracy   
  Drug Patients HUNT MUTARA 
 
Atorvastatin 
Older female  0.30 0.20 
Older male  0.30 0.20 
All patients (13712) 0.30 0.20 
 
Alendronate 
Older female  0.50 0.30 
Older male  0.40 0.20 
All patients (7569) 0.30 0.20 
 
 
Table 5.  The top 20 ADRs for Alendronate based on Student’s t-test. 
 Rank Readcodes Medical events NB NA R1(%) R2 (%) 
 
 
 
 
 
 
Level  
1-5 
1  1Z12.00           Chronic kidney disease stage 3      51     189    3.71      5.65 
  2  F4C0.00                     Acute conjunctivitis      30     125    4.17      3.74 
  3  M03z000                           Cellulitis NOS      37     152    4.11      4.54 
  4  1M10.00                                Knee pain      43     154    3.58      4.60 
  5  C10F.00                 Type 2 diabetes mellitus       7      44    6.29      1.32 
  6  H06z000                      Chest infection NOS      86     297    3.45      8.88 
  7  J16y400                                Dyspepsia      29     104    3.59      3.11 
  8  M0...00  Skin and subcutaneous tissue infections       9      65    7.22      1.94 
  9  182..00                               Chest pain      73     203    2.78      6.07 
 10  173I.00        MRC Breathlessness Scale: grade 2       9      43    4.78      1.29 
 11  N05..11                           Osteoarthritis      39     138    3.54      4.12 
 12  A53..11                                 Shingles      15      56    3.73      1.67 
 13  N131.00               Cervicalgia - pain in neck      48     132    2.75      3.95 
 14  G20..00                   Essential hypertension      30     116    3.87      3.47 
 15  1C14.00                            "Blocked ear"       5      39    7.80      1.17 
 16  1A55.00                                  Dysuria      21      76    3.62      2.27 
 17  F46..00                                 Cataract      14      67    4.79      2.00 
 18  K190.00 Urinary tract infection, site not specified      62     214    3.45      6.40 
 19  N143.00                                 Sciatica      33     103    3.12      3.08 
 20  AB2..12                                   Thrush      14      59    4.21      1.76 
 
 
 
 
1  1Z1..00                 Chronic renal impairment      58     237    4.09      7.08 
  2  183..00                                   Oedema      77     252    3.27      7.53 
  3  C10..00                        Diabetes mellitus      16      77    4.81      2.30 
  4  H05..00 Other acute upper respiratory infections      50     217    4.34      6.49 
  
 
 
 
Level  
1-3 
  5  173..00                           Breathlessness     127     386    3.04     11.54 
  6  M22..00                         Other dermatoses      43     181    4.21      5.41 
  7  171..00                                    Cough     161     472    2.93     14.11 
  8  19F..00                       Diarrhoea symptoms      64     225    3.52      6.72 
  9  1M1..00                       Pain in lower limb      49     172    3.51      5.14 
 10  F4C..00                 Disorders of conjunctiva      43     184    4.28      5.50 
 11  H06..00       Acute bronchitis and bronchiolitis     201     530    2.64     15.84 
 12  M03..00             Other cellulitis and abscess      46     181    3.93      5.41 
 13  AB0..00 Dermatophytosis including tinea or ringworm      22     102    4.64      3.05 
 14  N21..00 Peripheral enthesopathies and allied syndromes      52     154    2.96      4.60 
 15  N24..00              Other soft tissue disorders     229     573    2.50     17.12 
 16  168..00                        Tiredness symptom      67     217    3.24      6.49 
 17  19C..00                             Constipation      54     207    3.83      6.19 
 18  1A2..00                      Micturition control      15      75    5.00      2.24 
 19  1A1..00                    Micturition frequency      35     119    3.40      3.56 
 20  F56..00 Vertiginous syndromes, other disorders of vestibular 
system 
     19      79    4.16      2.36 
 
Table 6. The top 20 ADRs for Alendronate based on Wilcoxon rank-sum test. 
 Rank Readcodes Medical events NB NA R1(%) R2 (%) 
 
 
 
 
 
Level 1-5 
 1  1Z12.00           Chronic kidney disease stage 3      51     189    3.71      5.65 
  2  M0...00  Skin and subcutaneous tissue infections       9      65    7.22      1.94 
  3  M03z000                           Cellulitis NOS      37     152    4.11      4.54 
  4  F4C0.00                     Acute conjunctivitis      30     125    4.17      3.74 
  5  G20..00                   Essential hypertension      30     116    3.87      3.47 
  6  1M10.00                                Knee pain      43     154    3.58      4.60 
  7  C10F.00                 Type 2 diabetes mellitus       7      44    6.29      1.32 
  8  K190.00 Urinary tract infection, site not specified      62     214    3.45      6.40 
  9  F46..00                                 Cataract      14      67    4.79      2.00 
 10  H01..00                          Acute sinusitis      21      78    3.71      2.33 
 11  A53..11                                 Shingles      15      56    3.73      1.67 
 12  J16y400                                Dyspepsia      29     104    3.59      3.11 
 13  182..00                               Chest pain      73     203    2.78      6.07 
 14  K15..00                                 Cystitis      45     131    2.91      3.92 
 15  N143.00                                 Sciatica      33     103    3.12      3.08 
 16  1D14.00                              C/O: a rash      49     184    3.76      5.50 
 17  H06z000                      Chest infection NOS      86     297    3.45      8.88 
 18  N05..11                           Osteoarthritis      39     138    3.54      4.12 
 19  N131.00               Cervicalgia - pain in neck      48     132    2.75      3.95 
 20  173I.00        MRC Breathlessness Scale: grade 2       9      43    4.78      1.29 
 
 
 
Level 1-3 
1  1Z1..00                 Chronic renal impairment      58     237    4.09      7.08 
  2  H05..00 Other acute upper respiratory infections      50     217    4.34      6.49 
  3  M22..00                         Other dermatoses      43     181    4.21      5.41 
  4  C10..00                        Diabetes mellitus      16      77    4.81      2.30 
  5  H06..00       Acute bronchitis and bronchiolitis     201     530    2.64     15.84 
  6  183..00                                   Oedema      77     252    3.27      7.53 
  7  M03..00             Other cellulitis and abscess      46     181    3.93      5.41 
  8  19F..00                       Diarrhoea symptoms      64     225    3.52      6.72 
  9  173..00                           Breathlessness     127     386    3.04     11.54 
 10  K19..00 Other urethral and urinary tract disorders      82     297    3.62      8.88 
 11  M0...00  Skin and subcutaneous tissue infections       9      65    7.22      1.94 
 12  171..00                                    Cough     161     472    2.93     14.11 
 13  G20..00                   Essential hypertension      35     130    3.71      3.89 
 14  AB0..00 Dermatophytosis including tinea or ringworm      22     102    4.64      3.05 
 15  F4C..00                 Disorders of conjunctiva      43     184    4.28      5.50 
 16  1M1..00                       Pain in lower limb      49     172    3.51      5.14 
 17  1A2..00                      Micturition control      15      75    5.00      2.24 
 18  1A1..00                    Micturition frequency      35     119    3.40      3.56 
 19  F4D..00                  Inflammation of eyelids      26      86    3.31      2.57 
 20  19C..00                             Constipation      54     207    3.83      6.19 
 
Table 7. The top 20 ADRs  for Alendronate based on the descending order of R1 value.  
 Rank Readcodes Medical events NB NA R1 R2 
 
 
 
 
 
 
 
Level  
1-5 
1  F4K2100                      Vitreous detachment       1      23   23.00      0.69 
  2  N245.14                                Hand pain       1      20   20.00      0.60 
  3  K514.00       Uterovaginal prolapse, unspecified       0      18   18.00      0.54 
  4  16ZZ.00                      General symptom NOS       1      18   18.00      0.54 
  5  H040.00                         Acute laryngitis       1      17   17.00      0.51 
  6  N247012                        Swollen lower leg       0      17   17.00      0.51 
  7  1955.00                                Heartburn       1      17   17.00      0.51 
  8  F4C0311                               Sticky eye       1      17   17.00      0.51 
  9  M22z.12                         Seborrhoeic wart       1      17   17.00      0.51 
 10  S8z..13                               Laceration       1      16   16.00      0.48 
 11  J046.00        Temporomandibular joint disorders       0      14   14.00      0.42 
 12  173H.00        MRC Breathlessness Scale: grade 1       0      14   14.00      0.42 
 13  SE4..11                               Leg bruise       1      14   14.00      0.42 
 14  1B46.00                         C/O paraesthesia       1      14   14.00      0.42 
 15  G65..00             Transient cerebral ischaemia       1      14   14.00      0.42 
 16  1B16.11                       Agitated - symptom       1      14   14.00      0.42 
 17  1B6..13                        Vasovagal symptom       1      13   13.00      0.39 
 18  19A..00             Abdominal distension symptom       1      13   13.00      0.39 
 19  H32..00                                Emphysema       1      13   13.00      0.39 
 20  1AE..00                       Vaginal discomfort       1      12   12.00      0.36 
 
 
 
 
 
 
Level 
 1-3 
1  J04..00                    Dentofacial anomalies       0      16   16.00      0.48 
  2  BB5..00          [M]Adenomas and adenocarcinomas       1      16   16.00      0.48 
  3  A07..00 Intestinal infection due to other organisms       0      15   15.00      0.45 
  4  N35..00              Acquired deformities of toe       0      14   14.00      0.42 
  5  19A..00             Abdominal distension symptom       1      14   14.00      0.42 
  6  1M0..00                       Pain in upper limb       1      13   13.00      0.39 
  7  H32..00                                Emphysema       1      13   13.00      0.39 
  8  1J0..00                     Suspected malignancy       0      12   12.00      0.36 
  9  F11..00             Other cerebral degenerations       0      12   12.00      0.36 
 10  B22..00 Malignant neoplasm of trachea, bronchus and lung       1      12   12.00      0.36 
 11  1AE..00                       Vaginal discomfort       1      12   12.00      0.36 
 12  1CB..00                       Throat symptom NOS       2      22   11.00      0.66 
 13  A79..00                Specific viral infections       2      21   10.50      0.63 
 14  M0z..00     Skin and subcut tissue infection NOS       2      21   10.50      0.63 
 15  J02..00       Pulp and periapical tissue disease       1      10   10.00      0.30 
 16  B46..00           Malignant neoplasm of prostate       1      10   10.00      0.30 
 17  N36..00            Other acquired limb deformity       1      10   10.00      0.30 
 18  SE2..00                         Contusion, trunk       1       9    9.00      0.27 
 19  BB3..00                  [M]Basal cell neoplasms       1       9    9.00      0.27 
 20  15D..00                              Dyspareunia       0       9    9.00      0.27 
This table shows the top 20 results in descending order of R1 value for the detected results of Student’s t-test with p<0.05. 
 
 
Table 8. The top 20 ADRs for Metoclopramide based on Student’s t-test.   
 Rank Readcodes Medical events NB NA R1(%) R2 (%) 
 
 
 
Level 1-5 
 1  22J..14                              Patient died       2     101   50.50      1.21 
  2  22J..12                                    Death       1      72   72.00      0.87 
  3  B590.00              Disseminated malignancy NOS       7      33    4.71      0.40 
  4  H25..00 Bronchopneumonia due to unspecified organism       5      22    4.40      0.26 
  5  22J..13                                     Died       0      41   41.00      0.49 
  6  1737.00                                 Wheezing       2      13    6.50      0.16 
  7  M0z..11                  Infected sebaceous cyst       2      11    5.50      0.13 
  8  1D11.00                          C/O: a swelling       1      10   10.00      0.12 
  9  E2B..00                  Depressive disorder NEC      34      73    2.15      0.88 
 10  G65..00             Transient cerebral ischaemia       4      15    3.75      0.18 
 11  1B16.00                                 Agitated       3      14    4.67      0.17 
 12  G573200           Paroxysmal atrial fibrillation       0       6    6.00      0.07 
 13  1A24.11            Stress incontinence - symptom       0       6    6.00      0.07 
 14  J661.00                              Cholangitis       0       6    6.00      0.07 
 15  C320.00               Pure hypercholesterolaemia       4      16    4.00      0.19 
 16  2841.00                                 Confused       5      18    3.60      0.22 
 17  F13z200                   Restless legs syndrome       3      12    4.00      0.14 
 18  173I.00        MRC Breathlessness Scale: grade 2       1       8    8.00      0.10 
 19  M101.00                   Seborrhoeic dermatitis       2      10    5.00      0.12 
 20  1732.00           Breathless - moderate exertion       0       7    7.00      0.08 
 
 
 
 
 
 
 
Level 1-3 
 1  22J..00                               O/E - dead       3     221   73.67      2.66 
  2  1C1..00                         Hearing symptoms      17      41    2.41      0.49 
  3  F13..00 Other extrapyramidal disease and abnormal movement disorders       6      22    3.67      0.26 
  4  H25..00 Bronchopneumonia due to unspecified organism       5      22    4.40      0.26 
  5  K20..00             Benign prostatic hypertrophy       2      14    7.00      0.17 
  6  A38..00                              Septicaemia       3      16    5.33      0.19 
  7  284..00                      O/E - disorientated      12      29    2.42      0.35 
  8  SK1..00                   Other specified injury      20      45    2.25      0.54 
  9  E2B..00                  Depressive disorder NEC      34      74    2.18      0.89 
 10  C32..00           Disorders of lipoid metabolism      13      34    2.62      0.41 
 11  H54..00      Pulmonary congestion and hypostasis       0       6    6.00      0.07 
 12  F48..00                      Visual disturbances       8      22    2.75      0.26 
 13  K16..00               Other disorders of bladder       3      12    4.00      0.14 
 14  M21..00 Other atrophic and hypertrophic conditions of skin       7      19    2.71      0.23 
 15  N23..00    Muscle, ligament and fascia disorders      10      23    2.30      0.28 
 16  B59..00   Malignant neoplasm of unspecified site      24      72    3.00      0.87 
 17  F46..00                                 Cataract      11      27    2.45      0.32 
 18  F4K..00                      Other eye disorders       4      14    3.50      0.17 
 19  1A2..00                      Micturition control      14      31    2.21      0.37 
 20  M2y..00 Other specified diseases of skin or subcutaneous tissue      10      23    2.30      0.28 
 
Table 9. The top 20 ADRs for Metoclopramide based on Wilcoxon rank-sum test.  
 Rank Readcodes Medical events NB NA R1(%) 2 (%) 
 
 
 
 
 
 
 
 
 
Level 1-
5 
1 22J..14 Patient died 2 101 50.50 1.21 
2 22J..12 Death 1 72 72.00 0.87 
3 22J..13 Died 0 41 41.00 0.49 
4 B590.00 Disseminated malignancy NOS 7 33 4.71 0.40 
5 D00..00 Iron deficiency anaemias 18 38 2.11 0.46 
6 E2B..00 Depressive disorder NEC 34 73 2.15 0.88 
7 H25..00 Bronchopneumonia due to unspecified organism 5 22 4.40 0.26 
8 E200300 Anxiety with depression 20 44 2.20 0.53 
9 F46..00 Cataract 9 23 2.56 0.28 
10 G580.11 Congestive cardiac failure 7 19 2.71 0.23 
11 C320.00 Pure hypercholesterolaemia 4 16 4.00 0.19 
12 1B13.00 Anxiousness 13 30 2.31 0.36 
13 G65..00 Transient cerebral ischaemia 4 15 3.75 0.18 
14 B10..00 Malignant neoplasm of oesophagus 10 22 2.20 0.26 
15 M244.00 Folliculitis 7 18 2.57 0.22 
16 2841.00 Confused 5 18 3.60 0.22 
17 1B16.00 Agitated 3 14 4.67 0.17 
18 1737.00 Wheezing 2 13 6.50 0.16 
19 M0z..11 Infected sebaceous cyst 2 11 5.50 0.13 
20 F13z200 Restless legs syndrome 3 12 4.00 0.14 
 
 
 
 
Level 1-
3 
1 22J..00 O/E - dead 3 221 73.67 2.66 
2 1C1..00 Hearing symptoms 17 41 2.41 0.49 
3 C32..00 Disorders of lipoid metabolism 13 34 2.62 0.41 
4 F13..00 Other extrapyramidal disease and abnormal 
movement disorders 
6 22 3.67 0.26 
5 B59..00 Malignant neoplasm of unspecified site 24 72 3.00 0.87 
6 F46..00 Cataract 11 27 2.45 0.32 
7 1A2..00 Micturition control 14 31 2.21 0.37 
8 N23..00 Muscle, ligament and fascia disorders 10 23 2.30 0.28 
9 284..00 O/E - disorientated 12 29 2.42 0.35 
10 E2B..00 Depressive disorder NEC 34 74 2.18 0.89 
11 H25..00 Bronchopneumonia due to unspecified organism 5 22 4.40 0.26 
12 SK1..00 Other specified injury 20 45 2.25 0.54 
13 F48..00 Visual disturbances 8 22 2.75 0.26 
14 M2y..00 Other specified diseases of skin or subcutaneous 
tissue 
10 23 2.30 0.28 
15 M21..00 Other atrophic and hypertrophic conditions of skin 7 19 2.71 0.23 
16 K20..00 Benign prostatic hypertrophy 2 14 7.00 0.17 
17 A38..00 Septicaemia 3 16 5.33 0.19 
18 K16..00 Other disorders of bladder 3 12 4.00 0.14 
19 M10..00 Erythematosquamous dermatosis 9 20 2.22 0.24 
20 Eu4..00 [X]Neurotic, stress - related and somoform disorders 8 18 2.25 0.22 
 
Table 10. The top 20 ADRs for Metoclopramide based on the descending order of R1 value. 
 Rank Readcodes Medical events NB NA R1(%) R2 (%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1  22J..12                                    Death       1      72   72.00      0.87 
  2  22J..14                             Patient died       2     101   50.50      1.21 
  3  22J..13                                     Died       0      41   41.00      0.49 
  4  1D11.00                          C/O: a swelling       1      10   10.00      0.12 
  5  22J..00                               O/E - dead       0      10   10.00      0.12 
  6  A38..00                              Septicaemia       1       9    9.00      0.11 
  7  173I.00        MRC Breathlessness Scale: grade 2       1       8    8.00      0.10 
  8  L05..12                 Termination of pregnancy       1       8    8.00      0.10 
  9  19CZ.00                         Constipation NOS       1       8    8.00      0.10 
 10  1732.00           Breathless - moderate exertion       0       7    7.00      0.08 
 11  2225.00                         O/E - dehydrated       1       7    7.00      0.08 
 12  A54..00                           Herpes simplex       1       7    7.00      0.08 
 13  S8z..13                               Laceration       1       7    7.00      0.08 
 14  M18z.11                          Skin irritation       1       7    7.00      0.08 
 15  A38z.11                                   Sepsis       1       7    7.00      0.08 
 16  22K5.00            Body mass index 30+ - obesity       1       7    7.00      0.08 
 17  1737.00                                 Wheezing       2      13    6.50      0.16 
 18  G573200           Paroxysmal atrial fibrillation       0       6    6.00      0.07 
 19  1A24.11            Stress incontinence - symptom       0       6    6.00      0.07 
 20  J661.00                              Cholangitis       0       6    6.00      0.07 
  
 
 
 
 
 
 
Level 
1-3 
1  22J..00                               O/E - dead       3     221   73.67      2.66 
  2  K20..00             Benign prostatic hypertrophy       2      14    7.00      0.17 
  3  H54..00      Pulmonary congestion and hypostasis       0       6    6.00      0.07 
  4  E13..00               Other nonorganic psychoses       1       6    6.00      0.07 
  5  K12..00            Calculus of kidney and ureter       1       6    6.00      0.07 
  6  A38..00                              Septicaemia       3      16    5.33      0.19 
  7  H21..00           Lobar (pneumococcal) pneumonia       1       5    5.00      0.06 
  8  K56..00        Noninflammatory vaginal disorders       1       5    5.00      0.06 
  9  SK03.00       Post-traumatic wound infection NEC       1       5    5.00      0.06 
 10  A3Ay200          Clostridium difficile infection       0       5    5.00      0.06 
 11  1CE..00                         C/O - wax in ear       1       5    5.00      0.06 
 12  H25..00 Bronchopneumonia due to unspecified organism       5      22    4.40      0.26 
 13  K16..00               Other disorders of bladder       3      12    4.00      0.14 
 14  AC7..00           Other intestinal helminthiases       0       4    4.00      0.05 
 15  B6...00 Malignant neoplasm of lymphatic and 
haemopoietic tissue 
      0       4    4.00      0.05 
 16  L46..00 Obstetric breast and lactation disorders NOS       0       4    4.00      0.05 
 17  H52..00                             Pneumothorax       2       8    4.00      0.10 
 18  S8z..00   Open wound of head, neck and trunk NOS       2       8    4.00      0.10 
 19  L05..00                 Legally induced abortion       2       8    4.00      0.10 
 20  17...00                     Respiratory symptoms       1       4    4.00      0.05 
 
